i3 Health and Oncology Data Advisor Announce Release of Dedifferentiated Liposarcoma Position Statement and Podcast
Expert Perspectives · Keira Smith · 2024-12-04
i3 Health and Oncology Data Advisor are pleased to announce the publication of the Dedifferentiated Liposarcoma Task Force position statement in Cancer Treatment Reviews and the release of the Task Force podcast episode on i3Health.com.
The article, titled “Diagnosis and Management of Dedifferentiated Liposarcoma: A Multidisciplinary Position Statement,” is authored by the six Task Force members:
- Richard F. Riedel, MD, Associate Professor in the Division of Medical Oncology at Duke University Medical Center
- Candace L. Haddox, MD, Physician at Dana-Farber Cancer Institute and Instructor in Medicine at Harvard Medical School
- Elizabeth H. Baldini, MD, MPH, FASTRO, Professor of Radiation Oncology at Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Harvard Medical School
- Jason L. Hornick, MD, PhD, Professor of Pathology at Brigham and Women’s Hospital and Harvard Medical School
- Vicki L. Keedy, MD, MSCI, Associate Professor of Medicine and Clinical Director of Sarcoma at Vanderbilt-Ingram Cancer Center
- Christina L. Roland, MD, MS, FACS, Associate Professor in the Department of Surgical Oncology at MD Anderson Cancer Center
The Task Force also held a live YouTube discussion (@i3Health on YouTube) in which they shared insights into the optimal diagnosis, treatment, and management of dedifferentiated liposarcoma for improving patient outcomes. In the position statement, they further delve into clinical presentations, the role of oncogenes in pathogenesis and prognosis, diagnostic approaches, and multidisciplinary team management, highlighting the roles of pathology, surgery, radiation, and systemic therapy.
“Taking a multidisciplinary approach is crucial in optimizing the care of patients with dedifferentiated liposarcoma,” commented Dr. Riedel. “As treatment approaches become more refined, management has become increasingly nuanced, and collaboration between specialties is critical in addressing the complexities of this disease.”
“Our hope for this position statement is that it will encourage the multidisciplinary team to collaborate to ensure optimal outcomes for their patients as the treatment landscape continues to expand,” concluded Dr. Haddox.
Read the Dedifferentiated Liposarcoma Task Force position statement as an open-access article in Cancer Treatment Reviews today, and listen to the Task Force podcast episode in which Dr. Riedel and Dr. Haddox further explore the multidisciplinary management of dedifferentiated liposarcoma.